This is **Version 1.1** of the original hypothesis *"Systemic Lupus Erythematosus (SLE): A Platelet Disorder Hypothesis"*. This independent report serves as empirical clinical validation of the core hypothesis, leveraging real-world clinical cases and large-scale clinical data to confirm that SLE is fundamentally a bone marrow-driven platelet repair disorder, not a primary autoimmune disease. It demonstrates that targeted bone marrow restoration (via mesenchymal stem cell, MSC) and platelet function supplementation (via platelet-rich plasma, PRP) achieves profound clinical benefit, while conventional immunosuppression only addresses secondary immune activation and fails to achieve cure. This work strengthens the original hypothesis with robust clinical evidence, validating its pathogenic logic and therapeutic paradigm shift.
FOO SENG ANG (Sat,) studied this question.